Tarsus Pharmaceuticals, Inc. (TARS) Misses Q4 EPS by 12c
Tweet
Share
E-mailGet Alerts TARS Hot Sheet
Join SI Premium – FREE
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) reported Q4 EPS of ($0.20), $0.12 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $151.67 million versus the consensus estimate of $143.78 million.
For earnings history and earnings-related data on Tarsus Pharmaceuticals, Inc. (TARS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Movano (MOVE) Misses Q2 EPS by 195c
- Full Circle Lithium closes $5.14M private placement
- Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
